Reciprocal effects of scleroderma and temporomandibular dysfunction between patient cohorts

Pellicano, Chiara; Leodori, Giorgia; Floridia, Stefano; Colalillo, Amalia; Gigante, Antonietta; Rosato, Edoardo; Paoloni, Marco

doi:10.1080/08869634.2021.2019425

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 34 ] In patients with scleroderma, temporomandibular dysfunction reduces oral mobility and opening, resulting in further distension and bloating. [ 35 ] These patients further require health education to increase their dental care and salivary secretions to reduce their mouth dryness. However, the treatment strategies include rehabilitation via orofacial exercises and the administration of cevimeline, pilocarpine, muscarinic agonists, and artificial saliva.…”

Section: Gi Involvement and Its Management In Sscmentioning

confidence: 99%

Gastrointestinal involvement in systemic sclerosis: An updated review

et al. 2022

View full text Add to dashboard Cite

The gastrointestinal tract (GI) is the second most affected organ system in individuals suffering from systemic/localized scleroderma (SSc) or localized scleroderma. SSc can affect any part of the GI, between the oral cavity and anorectum. The annual incidence of SSc in the United States is estimated to be 19.3 cases per million adults, with the highest incidence reported in people aged 44 to 55. Females are 5 times more likely than males to suffer from SSc. Morbidity and mortality rates associated with SSc are predominantly elevated among patients with GI manifestations. Esophageal and intestinal manifestations impact 90% and 40% to 70% of patients with systemic scleroderma, respectively. SSc patients are known to suffer from small bowel hypomotility and small intestinal bacterial overgrowth, which cause malabsorption and malnutrition, ultimately contributing to the 50% mortality rate. Fecal incontinence is a common symptom of SSc that can lead to depression. SSc patients may suffer from gastrointestinal complications that can negatively impact their quality of life on a daily basis. Multidisciplinary approaches are necessary for systematically managing gastrointestinal complications associated with SSc. A prospective study should focus on developing targeted therapies to improve recovery patterns and prognosis in cases of SSc. This article summarizes the epidemiology, commonly reported clinical manifestations, complications, and available treatments for treating GI pathology in SSc patients.

show abstract

Section: Gi Involvement and Its Management In Sscmentioning

confidence: 99%